Cancer BiologybioRxivPreprint
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer
John T. Phoenix, Audris Budreika, Devin A. Schmeck…·Steven Kregel
This study identifies SOX2 and FOXA1 as a transcriptional partnership driving proliferation and lineage plasticity in therapy-resistant prostate cancer.
2 citations